ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
ICON talks about the inclusivity of decentralised trials
Patients as Partners Autumn newsletter features a Q&A with EB McLindon on the inclusivity of decentralised clinical trials.
Clinical trials shift to hybrid approaches in the age of COVID-19 and beyond
An article examining the state of clinical trials for orthopedics, featuring expert commentary from ICON's David T. Novotny, General Manager & Global Head, Medical Device & Diagnostic Research.
ICON: patient-centric trial network showing results
Alison Liddy, Senior VP of Site & Patient Solutions, discusses ICON's new Accellacare clinical research network, and the importance of patient centricity.
Engaging the crowds
A thought leadership piece by Peter Schueler which considers the importance of patient engagement and enrollment in Alzheimer's clinical trials.
Data capture in a post-digital clinical trial landscape
A thought leadership article authored by Tom O’Leary on how collected data from digital health technologies, coupled with novel clinical trial models, have the ability to increase the value proposition of drugs and medical devices.
Pharma and biotech companies are shifting from traditional trial models to agile, patient-centric processes driven by digital technologies to improve R&D productivity.
The quest for increased efficiency in personalised medicine clinical trials
A thought leadership piece discussing personalised medicine and how digital devices can improve treatment across a wide spectrum of conditions.
What will pandemic disruptions mean for EU IVDR?
An article outlining how IVD manufacturers must start prioritising product portfolios and conducting gap assessments now to ensure compliance by the May 2022 deadline.
Patient centricity: Exploring the patient perspective from different angles
An article exploring the challenges and potential solutions of integrating patient insight for improved outcomes from the perspective of a patient advocate, clinical investigator and pharmaceutical executive.
BARDA reselects ICON as preferred partner
An article focused on the BARDA announcement that ICON continues to be a part of The Clinical Trials Planning and Execution component of the CSN.